As of 2025-12-11, the EV/EBITDA ratio of Avidity Biosciences Inc (RNA) is -17.04. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Avidity's latest enterprise value is 10,400.86 mil USD. Avidity's TTM EBITDA according to its financial statements is -610.33 mil USD. Dividing these 2 quantities gives us the above Avidity EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.0x - 15.2x | 15.0x |
| Forward P/E multiples | 22.1x - 35.5x | 23.4x |
| Fair Price | (87.11) - (59.16) | (75.45) |
| Upside | -222.1% - -182.9% | -205.7% |
| Date | EV/EBITDA |
| 2025-12-10 | -17.04 |
| 2025-12-09 | -17.03 |
| 2025-12-08 | -17.02 |
| 2025-12-05 | -17.11 |
| 2025-12-04 | -17.09 |
| 2025-12-03 | -17.10 |
| 2025-12-02 | -17.09 |
| 2025-12-01 | -17.04 |
| 2025-11-28 | -17.13 |
| 2025-11-26 | -17.09 |
| 2025-11-25 | -17.09 |
| 2025-11-24 | -17.00 |
| 2025-11-21 | -16.85 |
| 2025-11-20 | -16.87 |
| 2025-11-19 | -16.93 |
| 2025-11-18 | -16.92 |
| 2025-11-17 | -16.88 |
| 2025-11-14 | -16.91 |
| 2025-11-13 | -16.92 |
| 2025-11-12 | -16.91 |
| 2025-11-11 | -16.88 |
| 2025-11-10 | -16.67 |
| 2025-11-07 | -16.67 |
| 2025-11-06 | -16.65 |
| 2025-11-05 | -16.66 |
| 2025-11-04 | -16.67 |
| 2025-11-03 | -16.66 |
| 2025-10-31 | -16.67 |
| 2025-10-30 | -16.63 |
| 2025-10-29 | -16.62 |
| 2025-10-28 | -16.69 |
| 2025-10-27 | -16.71 |
| 2025-10-24 | -11.56 |
| 2025-10-23 | -11.41 |
| 2025-10-22 | -11.00 |
| 2025-10-21 | -11.54 |
| 2025-10-20 | -11.53 |
| 2025-10-17 | -11.25 |
| 2025-10-16 | -11.47 |
| 2025-10-15 | -11.89 |
| 2025-10-14 | -11.31 |
| 2025-10-13 | -11.51 |
| 2025-10-10 | -11.71 |
| 2025-10-09 | -11.96 |
| 2025-10-08 | -11.34 |
| 2025-10-07 | -11.02 |
| 2025-10-06 | -10.83 |
| 2025-10-03 | -11.03 |
| 2025-10-02 | -10.33 |
| 2025-10-01 | -10.04 |